By blocking PD‑L1, the drug reverses PD‑1/PD‑L1 checkpoint inhibition, enabling cytotoxic T cells to kill PD‑L1–expressing tumor cells; additionally, its CD47 blockade promotes macrophage-mediated phagocytosis of PD‑L1/CD47 double‑positive cells.